Abu Dhabi, second in the world to adopt the population health model


The Abu Dhabi Ministry of Health (DoH) has confirmed that it has become the first healthcare regulatory body in the Middle East region – and the second in the world – to explore and adopt a population health model (PHM). The model, which is being developed in collaboration with Swiss company Novartis, will be dedicated to cardiovascular disease (CVD), focusing on early detection, management and prevention, the DoH announced.

“CVD is a major cause of death, hospitalization and poor quality of life in patients. Hence, it has become a key priority for health institutes in UAE [UAE] – and in particular the DoH – to seek new approaches to bend the curve of CVD events ”, explained Mohamed Ezz Eldin, president and head of the Gulf Cluster at Novartis. “The PHM is an alliance of healthcare ecosystems that offers a holistic approach to transforming the management of CVD patients in the United Arab Emirates. “

He continued, “The DoH is on its way to becoming the second largest healthcare system in the world after [the United Kingdom’s] NHS to explore the People’s Approach, strengthening their vision to drive innovation in the region. We are proud of this initiative which is part of a comprehensive mutual cooperation to add greater value to patients in Abu Dhabi.


Novartis describes the MPS as “an approach that supports local health partnerships to use data to develop proactive, rather than reactive models of care”.

It helps departments – such as local authorities, universities, industry leaders and charities – analyze this data to better understand local issues and thus work on tailor-made solutions to meet non-healthcare needs. satisfied.

Cardiovascular disease is defined as a group of disorders of the heart and blood vessels, which include coronary heart disease, cerebrovascular disease, and peripheral artery disease, among others.

According to the World Health Organization, cardiovascular disease is the leading cause of death worldwide, claiming an estimated 17.9 million lives each year. This figure is expected to reach around 23.6 million by 2030.

In the United Arab Emirates, CVD is believed to contribute an average of 40% of all deaths, with its incidence increasing in young adults.

It is hoped that the PHM will help “improve preventive measures against CVD and reduce the number of CVD cases and their complications among residents of the emirate,” the DoH said in a statement. It is “by providing data that allows health professionals to provide the necessary recommendations and prevention programs to patients.”


The latest announcement is part of DoH Abu Dhabi’s efforts to position the UAE capital “as a global healthcare destination and innovation incubator.”

The collaboration with Novartis “aims to invest in research, education, digital and organizational infrastructure to combat CVD and develop the emirate’s MPS program.”


“Under the guidance of our wise leadership and guidance, we continue to build strong and successful collaborations with partners around the world to improve the efficiency of the healthcare system and maintain the health and safety of our community,” said declared HE Abdulla bin Mohamed Al Hamed. , president of DoH Abu Dhabi. “The department will continue to adopt advanced innovations and partner with relevant entities to help us achieve our goal of positioning the emirate as a global healthcare hub while improving the future of the healthcare system. health. “


Comments are closed.